Somatostatin and somatostatin receptors: Implications for neoplastic growth and cancer biology

Pavlos Msaouel, Evanthia Galanis, Michael Koutsilieris

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Somatostatin agonists (SM-As) are capable of achieving durable symptomatic relief and significant clinical responses in certain tumours. Herein, we review the diverse direct and indirect mechanisms of antineoplastic activity elicited by SM-As as well as the hurdles that complicate their use as monotherapies in a broader range of malignancies. Emphasis is placed on recent clinical attempts to neutralise the IGF-mediated survival factor effects in the bone metastasis microenvironment in advanced prostate cancer. The first clinical trials of this 'anti-survival factor manipulation' strategy utilised the ability of SM-As to suppress the growth hormone-dependent liver-derived IGF-I bioavailability in combination with other drugs, such as dexamethasone, zolendronate and oestrogens, acting systemically and at the bone metastasis microenvironment. These regimens restored androgen ablation responsiveness in stage D3 prostate cancer patients and successfully produced objective clinical responses while only mild toxicities were observed. Furthermore, we focus on the preclinical experimental data of a targeted SM-A coupled to the super-potent doxorubicin derivative AN-201. The resulting conjugate (AN-238) has shown increased antitumour potency with a favourable toxicity profile. The potential use of novel SM-As as anticancer drugs is discussed in relation to data suggesting other direct and indirect treatment approaches pertaining to the somatostatin system.

Original languageEnglish (US)
Pages (from-to)1297-1316
Number of pages20
JournalExpert Opinion on Investigational Drugs
Volume18
Issue number9
DOIs
StatePublished - Sep 2009

Fingerprint

Somatostatin Receptors
Somatostatin
Growth
Neoplasms
Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Survival
Insulin-Like Growth Factor I
Pharmaceutical Preparations
Antineoplastic Agents
Doxorubicin
Dexamethasone
Biological Availability
Androgens
Growth Hormone
Estrogens
Clinical Trials
Liver

Keywords

  • Anticancer targets
  • Somatostatin
  • Somatostatin receptor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Somatostatin and somatostatin receptors : Implications for neoplastic growth and cancer biology. / Msaouel, Pavlos; Galanis, Evanthia; Koutsilieris, Michael.

In: Expert Opinion on Investigational Drugs, Vol. 18, No. 9, 09.2009, p. 1297-1316.

Research output: Contribution to journalArticle

@article{eb250ab9037d4d72933fb435b430fe79,
title = "Somatostatin and somatostatin receptors: Implications for neoplastic growth and cancer biology",
abstract = "Somatostatin agonists (SM-As) are capable of achieving durable symptomatic relief and significant clinical responses in certain tumours. Herein, we review the diverse direct and indirect mechanisms of antineoplastic activity elicited by SM-As as well as the hurdles that complicate their use as monotherapies in a broader range of malignancies. Emphasis is placed on recent clinical attempts to neutralise the IGF-mediated survival factor effects in the bone metastasis microenvironment in advanced prostate cancer. The first clinical trials of this 'anti-survival factor manipulation' strategy utilised the ability of SM-As to suppress the growth hormone-dependent liver-derived IGF-I bioavailability in combination with other drugs, such as dexamethasone, zolendronate and oestrogens, acting systemically and at the bone metastasis microenvironment. These regimens restored androgen ablation responsiveness in stage D3 prostate cancer patients and successfully produced objective clinical responses while only mild toxicities were observed. Furthermore, we focus on the preclinical experimental data of a targeted SM-A coupled to the super-potent doxorubicin derivative AN-201. The resulting conjugate (AN-238) has shown increased antitumour potency with a favourable toxicity profile. The potential use of novel SM-As as anticancer drugs is discussed in relation to data suggesting other direct and indirect treatment approaches pertaining to the somatostatin system.",
keywords = "Anticancer targets, Somatostatin, Somatostatin receptor",
author = "Pavlos Msaouel and Evanthia Galanis and Michael Koutsilieris",
year = "2009",
month = "9",
doi = "10.1517/13543780903176399",
language = "English (US)",
volume = "18",
pages = "1297--1316",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Somatostatin and somatostatin receptors

T2 - Implications for neoplastic growth and cancer biology

AU - Msaouel, Pavlos

AU - Galanis, Evanthia

AU - Koutsilieris, Michael

PY - 2009/9

Y1 - 2009/9

N2 - Somatostatin agonists (SM-As) are capable of achieving durable symptomatic relief and significant clinical responses in certain tumours. Herein, we review the diverse direct and indirect mechanisms of antineoplastic activity elicited by SM-As as well as the hurdles that complicate their use as monotherapies in a broader range of malignancies. Emphasis is placed on recent clinical attempts to neutralise the IGF-mediated survival factor effects in the bone metastasis microenvironment in advanced prostate cancer. The first clinical trials of this 'anti-survival factor manipulation' strategy utilised the ability of SM-As to suppress the growth hormone-dependent liver-derived IGF-I bioavailability in combination with other drugs, such as dexamethasone, zolendronate and oestrogens, acting systemically and at the bone metastasis microenvironment. These regimens restored androgen ablation responsiveness in stage D3 prostate cancer patients and successfully produced objective clinical responses while only mild toxicities were observed. Furthermore, we focus on the preclinical experimental data of a targeted SM-A coupled to the super-potent doxorubicin derivative AN-201. The resulting conjugate (AN-238) has shown increased antitumour potency with a favourable toxicity profile. The potential use of novel SM-As as anticancer drugs is discussed in relation to data suggesting other direct and indirect treatment approaches pertaining to the somatostatin system.

AB - Somatostatin agonists (SM-As) are capable of achieving durable symptomatic relief and significant clinical responses in certain tumours. Herein, we review the diverse direct and indirect mechanisms of antineoplastic activity elicited by SM-As as well as the hurdles that complicate their use as monotherapies in a broader range of malignancies. Emphasis is placed on recent clinical attempts to neutralise the IGF-mediated survival factor effects in the bone metastasis microenvironment in advanced prostate cancer. The first clinical trials of this 'anti-survival factor manipulation' strategy utilised the ability of SM-As to suppress the growth hormone-dependent liver-derived IGF-I bioavailability in combination with other drugs, such as dexamethasone, zolendronate and oestrogens, acting systemically and at the bone metastasis microenvironment. These regimens restored androgen ablation responsiveness in stage D3 prostate cancer patients and successfully produced objective clinical responses while only mild toxicities were observed. Furthermore, we focus on the preclinical experimental data of a targeted SM-A coupled to the super-potent doxorubicin derivative AN-201. The resulting conjugate (AN-238) has shown increased antitumour potency with a favourable toxicity profile. The potential use of novel SM-As as anticancer drugs is discussed in relation to data suggesting other direct and indirect treatment approaches pertaining to the somatostatin system.

KW - Anticancer targets

KW - Somatostatin

KW - Somatostatin receptor

UR - http://www.scopus.com/inward/record.url?scp=68849130986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68849130986&partnerID=8YFLogxK

U2 - 10.1517/13543780903176399

DO - 10.1517/13543780903176399

M3 - Article

C2 - 19678799

AN - SCOPUS:68849130986

VL - 18

SP - 1297

EP - 1316

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 9

ER -